The American Cancer Society reported earlier this year that the risk of dying from cancer in the United States has decreased by 32% over the past 28 years, which translates to almost 3.5 million fewer cancer deaths. Over these nearly three decades, cancer treatment options have increased immensely. For example, oral oncolytic medications now enable patients to receive therapies that target specific mutations in their tumors in pill form, replacing time-intensive chemotherapy infusions and minimizing side effects. New technologies, such as genome testing and artificial intelligence, have sharpened our view of cancer.
Michael Diaz, MD and Faithlore Gardner, MD from Florida Cancer Specialists & Research Institute (FCS) participated in the Florida Society of Clinical Oncology (FLASCO) Fellow & Resident Educational Training Program held March 19, 2022 in Orlando, Florida.
Florida Cancer Specialists & Research Institute (FCS) launched a new website, Florida Cancer Specialists Hematology Oncology Review (FCSHemOncReview.com), to host a variety of top articles ranging from recent oncology and hematology studies to new therapies, even topics on value-based care.
Physicians and senior leaders of Florida Cancer Specialists & Research Institute (FCS) will be participating in the 2022 Community Oncology Conference hosted by the Community Oncology Alliance (COA) this week in Kissimmee, Florida.
Florida Cancer Specialists & Research Institute (FCS) is pleased to welcome Ken Sturtz, MBA, MHA to its executive leadership team as Chief Information Officer. He will oversee all information technology operations and drive digital innovation company-wide.
Three Florida Cancer Specialists & Research Institute (FCS) physicians presented clinical research findings at the American Society of Clinical Oncology (ASCO®) 2022 Genitourinary Cancers Symposium held February 17 – 19 in San Francisco, CA.
Medical oncologists Lucio N. Gordan, MD and Ivor Percent, MD, members of the clinical research team at Florida Cancer Specialists & Research Institute (FCS), are co-authors for a study that examined the safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC) administered primarily in community-based settings.
Lime Connect (Lime) is pleased to announce that Nathan H. Walcker, Chief Executive Officer of Florida Cancer Specialists & Research Institute, has joined the not for profit organization as a member of its global board of directors.
FCS Top News Updates
FCS Expands Footprint Into St. Lucie County, Breaks Ground For New Cancer Center in Tradition
Advancing Cancer Care Through Clinical Trials in a Community Oncology SettingThe American Cancer Society reported earlier this year that the risk of dying from cancer in the United States has decreased by 32% over the past 28 years, which translates to almost 3.5 million fewer cancer deaths. Over these nearly three decades, cancer treatment options have increased immensely. For example, oral oncolytic medications now enable patients to receive therapies that target specific mutations in their tumors in pill form, replacing time-intensive chemotherapy infusions and minimizing side effects. New technologies, such as genome testing and artificial intelligence, have sharpened our view of cancer.
Florida Cancer Specialists & Research Institute Physicians Serve as Panelists for FLASCO Training ProgramMichael Diaz, MD and Faithlore Gardner, MD from Florida Cancer Specialists & Research Institute (FCS) participated in the Florida Society of Clinical Oncology (FLASCO) Fellow & Resident Educational Training Program held March 19, 2022 in Orlando, Florida.
Florida Cancer Specialists & Research Institute Launches FCS Hematology Oncology ReviewFlorida Cancer Specialists & Research Institute (FCS) launched a new website, Florida Cancer Specialists Hematology Oncology Review (FCSHemOncReview.com), to host a variety of top articles ranging from recent oncology and hematology studies to new therapies, even topics on value-based care.
Florida Cancer Specialists & Research Institute Leaders Participating in Community Oncology Alliance Annual ConferencePhysicians and senior leaders of Florida Cancer Specialists & Research Institute (FCS) will be participating in the 2022 Community Oncology Conference hosted by the Community Oncology Alliance (COA) this week in Kissimmee, Florida.
Florida Cancer Specialists & Research Institute Welcomes Ken Sturtz, MBA, MHA as Chief Information OfficerFlorida Cancer Specialists & Research Institute (FCS) is pleased to welcome Ken Sturtz, MBA, MHA to its executive leadership team as Chief Information Officer. He will oversee all information technology operations and drive digital innovation company-wide.
Florida Cancer Specialists & Research Institute Studies Featured at ASCO® Genitourinary Cancers SymposiumThree Florida Cancer Specialists & Research Institute (FCS) physicians presented clinical research findings at the American Society of Clinical Oncology (ASCO®) 2022 Genitourinary Cancers Symposium held February 17 – 19 in San Francisco, CA.
Lucio Gordan, MD, Ivor Percent, MD Co-Author Phase 3b/4 Renal Cell Carcinoma StudyMedical oncologists Lucio N. Gordan, MD and Ivor Percent, MD, members of the clinical research team at Florida Cancer Specialists & Research Institute (FCS), are co-authors for a study that examined the safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC) administered primarily in community-based settings.
Nathan H. Walcker joins Lime Connect Global Board of DirectorsLime Connect (Lime) is pleased to announce that Nathan H. Walcker, Chief Executive Officer of Florida Cancer Specialists & Research Institute, has joined the not for profit organization as a member of its global board of directors.